The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

By sjmartinez • February 12, 2024

Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects. Eur J Cancer. 2024 Mar;199:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. PMID: 38262306.

Tags: Bispecific antibodies, CAR-T-cells, checkpoint inhibitors, Data base, Hematology/Oncology, immune-related adverse events, Online registry, Publications

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML

Zeidner JF, Lin TL, Welkie RL, Curran E, Koenig K, Stock W, Madanat YF, Swords R, Baer MR, Blum W, Stein EM, Olin RL, Schiller[...]

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

Guo Q, Parikh K, Zhang J, Brinkley A, Chen G, Jakramonpreeya N, Zhen A, An DS. Anti-HIV-1 HSPC-based gene therapy with safety kill switch to[...]

Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer

Silverstein J, Smick A, Johnson B, Konecny GE. Mirvetuximab soravtansine for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer. Future Oncol. 2025[...]